1/8
08:30 am
xlo
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Low
Report
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
12/30
04:16 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
04:43 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
03:47 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
02:24 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
07:30 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Medium
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results